{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:34:45Z","timestamp":1792172085383,"version":"4.4.0"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T00:00:00Z","timestamp":1645747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p><jats:sup>11<\/jats:sup>C-Methionine (<jats:sup>11<\/jats:sup>C-MET) PET prognostication of isocitrate dehydrogenase (IDH) wild type glioblastomas is inadequate as conventional parameters such as standardized uptake value (SUV) do not adequately reflect tumor heterogeneity. We retrospectively evaluated whether volume-based parameters such as metabolic tumor volume (MTV) and total lesion methionine metabolism (TLMM) outperformed SUV for survival correlation in patients with IDH wild type glioblastomas.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Thirteen IDH wild type glioblastoma patients underwent preoperative <jats:sup>11<\/jats:sup>C-MET PET. Both SUV-based parameters and volume-based parameters were calculated for each lesion. Kaplan-Meier curves with log-rank testing and Cox regression analysis were used for correlation between PET parameters and overall survival.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Median overall survival for the entire cohort was 393 days. MTV (HR 1.136, p = 0.007) and TLMM (HR 1.022, p = 0.030) were inversely correlated with overall survival. SUV-based <jats:sup>11<\/jats:sup>C-MET PET parameters did not show a correlation with survival. In a paired analysis with other clinical parameters including age and radiotherapy dose, MTV and TLMM were found to be independent factors.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>MTV and TLMM, and not SUV, significantly correlate with overall survival in patients with IDH wild type glioblastomas. The incorporation of volume-based <jats:sup>11<\/jats:sup>C-MET PET parameters may lead to a better outcome prediction for this heterogeneous patient population.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0264387","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T18:35:18Z","timestamp":1645814118000},"page":"e0264387","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prognostic value of 11C-methionine volume-based PET parameters in IDH wild type glioblastoma"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4804-7276","authenticated-orcid":true,"given":"Bart R. J.","family":"van Dijken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred O.","family":"Ankrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles N.","family":"Stormezand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi A. J. O.","family":"Dierckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jan van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"van der Hoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,25]]},"reference":[{"key":"pone.0264387.ref001","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/neuonc\/now058","article-title":"Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas","volume":"18","author":"NL Albert","year":"2016","journal-title":"Neuro Oncol"},{"key":"pone.0264387.ref002","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00259-012-2295-5","article-title":"Value of 11C-methionine PET in imaging brain tumours and metastases","volume":"40","author":"AWJM Glaudemans","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0264387.ref003","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0140-6736(17)31442-3","article-title":"Interim results from the CATNON trial (EORTC study 26053\u201322054) of treatment with concurrent and adjuvant temozolomide for 1p\/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study","volume":"390","author":"MJ van den Bent","year":"2017","journal-title":"Lancet"},{"key":"pone.0264387.ref004","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"DN Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"pone.0264387.ref005","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma Groups Based on 1p\/19q, IDH, and TERT Promoter Mutations in Tumors","volume":"372","author":"JE Eckel-Passow","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0264387.ref006","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13550-019-0481-1","article-title":"Repeatability of [18 F]FDG PET\/CT Total Metabolic Active Tumour Volume and Total Tumour Burden in NSCLC Patients","volume":"9","author":"KD Guilherme","year":"2019","journal-title":"EJNMMI Res"},{"key":"pone.0264387.ref007","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s00259-015-3046-1","article-title":"Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients","volume":"42","author":"K Kobayashi","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0264387.ref008","first-page":"291","volume":"49","author":"MY Yoo","year":"2015","journal-title":"Prognostic Value of Metabolic Tumor Volume on (11)C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma"},{"key":"pone.0264387.ref009","first-page":"1037","article-title":"Synthesis of L- and D-[methyl-11C]methionine","volume":"28","author":"B Langstrom","year":"1987","journal-title":"J Nucl Med"},{"key":"pone.0264387.ref010","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s00259-006-0206-3","article-title":"EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues","volume":"33","author":"T Vander Borght","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0264387.ref011","first-page":"1432","article-title":"[11C]methionine PET, Histopathology, and Survival in Primary Brain Tumors and Recurrence","volume":"27","author":"S Ceyssens","year":"2006","journal-title":"AJNR Am J Neuroradiol"},{"key":"pone.0264387.ref012","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clineuro.2015.10.035","article-title":"Role of [(11)C] Methionine Positron Emission Tomography in the Diagnosis and Prediction of Survival in Brain Tumours","volume":"139","author":"M Cicuendez","year":"2015","journal-title":"Clin Neurol Neurosurg"},{"key":"pone.0264387.ref013","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00259-017-3618-3","article-title":"Prognostic Value of Molecular and Imaging Biomarkers in Patients With Supratentorial Glioma","volume":"44","author":"E Lopci","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0264387.ref014","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/neuonc\/nox177","article-title":"Visual and Semiquantitative 11C-methionine PET: An Independent Prognostic Factor for Survival of Newly Diagnosed and Treatment-Na\u00efve Gliomas","volume":"20","author":"N Poetsch","year":"2018","journal-title":"Neuro Oncol"},{"key":"pone.0264387.ref015","first-page":"1","article-title":"Usefulness of Positron Emission Tomography for Differentiating Gliomas According to the 2016 World Health Organization Classification of Tumors of the Central Nervous System","volume":"16","author":"H Takei","year":"2019","journal-title":"J Neurosurg"},{"key":"pone.0264387.ref016","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13550-020-00633-1","article-title":"Diagnostic Value of PET\/CT With 11C-methionine (MET) and 18 F-fluorothymidine (FLT) in Newly Diagnosed Glioma Based on the 2016 WHO Classification","volume":"10","author":"T Ogawa","year":"2020","journal-title":"EJNMMI Res"},{"key":"pone.0264387.ref017","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0000000000001262","article-title":"Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM","volume":"84","author":"B Suchorska","year":"2015","journal-title":"Neurology"},{"key":"pone.0264387.ref018","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s00259-020-04695-0","article-title":"Prediction of survival in patients with IDH-wildtype astrocytic gliomas using dynamic O-(2- [18 F]-fluoroethyl)-L-tyrosine PET","volume":"47","author":"EK Bauer","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"pone.0264387.ref019","doi-asserted-by":"crossref","first-page":"918","DOI":"10.2967\/jnumed.120.254243","article-title":"Early Treatment Response Assessment Using 18 F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy","volume":"62","author":"G Ceccon","year":"2021","journal-title":"J Nucl Med"},{"key":"pone.0264387.ref020","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/cancers12041042","article-title":"18F-FDG and 11C-Methionine PET\/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers","volume":"12","author":"MIM Morales-Lozano","year":"2020","journal-title":"Cancers (Basel)"},{"key":"pone.0264387.ref021","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1097\/RLU.0000000000002733","article-title":"Influence of Biological Parameters Assessed in [18F]FDG PET\/CT on Overall Survival in Cervical Cancer Patients","volume":"44","author":"P Cegla","year":"2019","journal-title":"Clin Nucl Med"},{"key":"pone.0264387.ref022","article-title":"Prognostic Role of Positron Emission Tomography and Computed Tomography Parameters in Stage I Lung Adenocarcinoma","author":"A Carretta","year":"2020","journal-title":"Radiol Oncol"},{"key":"pone.0264387.ref023","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoto.2020.0014","article-title":"Evaluation of the Prognostic Value of FDG PET\/CT Parameters for Patients With Surgically Treated Head and Neck Cancer: A Systematic Review","volume":"146","author":"G Creff","year":"2020","journal-title":"JAMA Otolaryngol Head Neck Surg"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T18:35:40Z","timestamp":1645814140000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0264387"}},"subtitle":[],"editor":[{"given":"Kevin","family":"Camphausen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,25]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0264387","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,25]]}}}